As of 2022, GLP-1RAs have been recommended as first-line treatments, along with SGLT-2 inhibitors, for patients with T2DM and cardiovascular disease in American Diabetes Associations Standards of Medical Care in Diabetes (248, 249)
After receiving your first Semaglutide (GLP-1) injection, the medication begins working within hours by mimicking the natural GLP-1 hormone in your body
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors, currently in clinical development for obesity and type 2 diabetes
Pregnancy safety recommendations for compounded versions: The same general washout timeline appliesstop at least 2 months before planned conception for semaglutide-based compounds, and follow similar timing for tirzepatide-based compounds
the term 'triple incretin agonist' sometimes used in lay media is therefore imprecise
She exercised and watched what she ate, but she wasnt losing weight and her mental health suffered